624 results on '"Carrier, Lucie"'
Search Results
102. Analysis of Contractile Function of Permeabilized Human Hypertrophic Cardiomyopathy Multicellular Heart Tissue
103. The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM
104. Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes—a systematic review
105. Treatments targeting inotropy
106. The COX8 gene is not the disease gene of the CMH4 locus in familial hypertrophic cardiomyopathy
107. Familial Hypertrophic Cardiomyopathy: Microsatellite Haplotyping and Identification of a Hot Spot for Mutations in the Beta-Myosin Heavy Chain Gene
108. Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy
109. S100A4 as a Target of the E3-Ligase Asb2β and Its Effect on Engineered Heart Tissue
110. Gene therapy strategies in the treatment of hypertrophic cardiomyopathy
111. CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy
112. Erratum to: How do MYBPC3 mutations cause hypertrophic cardiomyopathy?
113. Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
114. Evaluation of MYBPC3 trans -Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes
115. Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae
116. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3 -knock-in mice
117. Epigallocatechin-3-Gallate Accelerates Relaxation and Ca2+ Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice
118. The embryological basis of subclinical hypertrophic cardiomyopathy
119. S ‐glutathiolation impairs phosphoregulation and function of cardiac myosin‐binding protein C in human heart failure
120. Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function inMybpc3-targeted HCM mouse model
121. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology
122. Abstract 19161: cAMP Regulated Transcriptional Coactivator 1 - A Novel Player in Cardiac Hypertrophy
123. Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effectsin vivoin a mouse model of hypertrophic cardiomyopathy
124. PLEKHM2mutation leads to abnormal localization of lysosomes, impaired autophagy flux and associates with recessive dilated cardiomyopathy and left ventricular noncompaction
125. Targeted Mybpc3 Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve Abnormalities
126. MYBPC3 Gene Therapy for Neonatal Sarcomeric Cardiomyopathies
127. Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy
128. Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms
129. Endothelin‐1 Induces Myofibrillar Disarray and Contractile Vector Variability in Hypertrophic Cardiomyopathy–Induced Pluripotent Stem Cell–Derived Cardiomyocytes
130. Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy
131. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice
132. Epigallocatechin-3-Gallate Accelerates Relaxation and Ca2+ Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice.
133. Genetic Basis and Genotype-Phenotype Relationships in Familial Hypertrophic Cardiomyopathy
134. Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice
135. Automated analysis of contractile force and Ca2+transients in engineered heart tissue
136. Exercise-Induced Enhancement of Cardiac and Sarcomere Performance is Larger in Male than in Female MYBPC3 Mutation Heterozyous Knock-In Mice
137. MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction
138. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice
139. The expression of podocyte-specific proteins in parietal epithelial cells is regulated by protein degradation
140. Perturbed Length-Dependent Activation in Human Hypertrophic Cardiomyopathy With Missense Sarcomeric Gene Mutations
141. Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP)-mediated Calcium Signaling and Arrhythmias in the Heart Evoked by β-Adrenergic Stimulation
142. AT1 blockade abolishes left ventricular hypertrophy in heterozygous cMyBP-C null mice: role of FHL1
143. GSK3β Phosphorylates Newly Identified Site in the Proline-Alanine–Rich Region of Cardiac Myosin–Binding Protein C and Alters Cross-Bridge Cycling Kinetics in Human
144. Distinctive Serum miRNA Profile in Mouse Models of Striated Muscular Pathologies
145. The HCM-Associated Cardiac Troponin T Mutation K280N Increases the Energetic Cost of Tension Generation in Human Cardiac Myofibrils
146. Repair of Mybpc3 mRNA by 5′-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy
147. Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model.
148. Knock-out of nexilin in mice leads to dilated cardiomyopathy and endomyocardial fibroelastosis.
149. Genetics of Hypertrophic and Dilated Cardiomyopathy
150. Pharmacological Characterization of 1-Nitrosocyclohexyl Acetate, a Long-Acting Nitroxyl Donor That Shows Vasorelaxant and Antiaggregatory Effects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.